Faculty, Staff and Student Publications

Publication Date

4-17-2025

Journal

Journal of Hematology & Oncology

Abstract

The clinical utility of liquid biopsy (LB) for pancreatic ductal adenocarcinoma (PDAC) remain understudied. Our single-institution cohort of 311 PDAC patients with non-tumor tissues informed LB found 81.2% positivity (N = 186) in metastatic cases and in 52.4% (N = 43) of localized disease. KRAS mutations were detected in 64.6% (N = 148) of metastatic cases and 16% (N = 13) for localized disease. Positive LB, especially KRAS mutation detection, is associated with worse overall survival (OS) in metastatic PDAC (median 14.5 vs. 31.3 months, HR = 2.7, 95%CI = 1.7-4.3, P <  0.0001). The positive concordance rates of KRAS and TP53 mutations were 63% and 68% in metastatic disease but only 7% (KRAS) and 33% (TP53) in localized disease, respectively. Among the 41 patients who underwent serial liquid biopsy testing, 25% tested positive after an initial negative result. LB detects therapeutically targetable mutations in 58.5% of PDAC patients and is associated with OS.

Keywords

Humans, Carcinoma, Pancreatic Ductal, Proto-Oncogene Proteins p21(ras), Liquid Biopsy, Pancreatic Neoplasms, Mutation, Female, Male, Aged, Middle Aged, Aged, 80 and over, Adult, Pancreatic cancer, Liquid biopsy, KRAS, PDAC, Molecular profiling, Mutation, OS

DOI

10.1186/s13045-025-01696-0

PMID

40247392

PMCID

PMC12004821

PubMedCentral® Posted Date

4-17-2025

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.